CAPR Stock Capricor Therapeutics, Inc.
Today’s call · CAPR
All live ideas →5 of 6 technical checks lean bearish
CAPR is in a downtrend, momentum soft. $8 is the level overhead; $7 the first support below.
- A close below $7 on rising volume (breakdown).
- A bounce to $8 that fails (entry near resistance).
The brief
All readings
Levels that matter
Compare with…
Latest news
Capricor Therapeutics (CAPR) stock analysis, November 15, 2026: neutral outlook, low conviction
Capricor Therapeutics (CAPR) slipped to $9.53 on November 13, a 6.9% one‑day drop that left the stock 15% below its recent peak of $11.22. The price remains well under its 40‑week average, keeping the long‑term trend down, while a short‑term rally has lifted the stock above the 50‑day SMA and outperformed the S&P 500 over the past 50 days. The balance of evidence points to a neutral stance with low conviction for the next two to six weeks.
Why it matters
The immediate catalyst was a sharp intraday sell‑off that pushed the close below the $10 round level, a zone where sellers have historically stepped in on rallies. The move was not driven by any new corporate news; the news feed shows no announcements, earnings releases, or sector‑wide events that would explain the drop. In the absence of a fundamental trigger, the market reaction appears to be a technical correction after a brief bounce.
Even though the stock fell, it still outperformed the broader market. Over the past five days CAPR gained 5.9% versus a 2.6% rise in the S&P 500 and a 2.2% rise in the health‑care sector ETF XLV. The outperformance is reflected in the 5‑day attribution numbers: the stock contributed an extra 3.7 percentage points over the sector, indicating that the rally was driven more by the stock itself than by sector momentum.
Analyst sentiment remains broadly positive, with six analysts rating the stock a buy and a mean price target of $27.25. That target is 65% above the current price, suggesting a large valuation gap. However, the consensus target range ($10.5‑$54) is wide, and the low‑end target sits only modestly above the $10 resistance level that has capped recent upside.
The debate among market participants centers on whether the recent rally is sustainable. One side points to the 19.1% outperformance versus the S&P 500 over 50 days and the 8.8% edge versus XLV, arguing that the stock is carving a niche despite the downtrend. The opposing view stresses that the price is still below both its 40‑week average and the 200‑day SMA ($19.96), that volume is 7.8% below its 20‑day average, and that the recent drop from the $11.22 peak was 15%, a move that historically precedes a further month‑long decline in 70.9% of cases.
What the evidence says
On the long‑term horizon the thesis that CAPR is in a downtrend remains intact. The price sits below the 40‑week average, the 200‑day SMA sits at $19.96, and the 52‑week low of $3.85 is still far away, indicating that the stock has ample downside room but no sign of a trend reversal.
For the next two to six weeks the balance of evidence leans neutral with low conviction. The assessment notes a rally against the weekly downtrend that is not yet stretched, and the breakout math points to a downside bias: a daily close below $9.0 would trigger the downside breakout, with a stop at $10.26 and two targets at $8.10 (SMA‑50) and $3.85 (52‑week low). The math meets a 3‑to‑1 reward‑to‑risk ratio, but only because the lower target offers a 4.1‑to‑1 payoff; the nearer target provides only 0.7‑to‑1, keeping conviction low.
The strongest case against a neutral reading is the 15% drop from the recent peak and the fact that a one‑day move of more than 5% has historically been followed by a 61.8% decline over the next month. Those numbers suggest that the downside risk is real, but the low conviction reflects that the probability of a further slide is not overwhelming given the short‑term outperformance.
Levels that matter
The structure holds the price above the $10 round level, a zone where sellers have repeatedly emerged on rallies. The weekly trend would be considered ended if the price closes above the $25.65 swing‑zone, a level that sits well above current levels and would signal a major shift in momentum.
The breakout math focuses on a daily close below $9.0 as the trigger for a downside breakout. The stop is set at $10.26, calculated as $10.0 plus a quarter of the 14‑day ATR ($1.04). The first target is $8.10, the 50‑day SMA, offering a reward‑to‑risk of 0.7. The deeper target is $3.85, the 52‑week low, with a reward‑to‑risk of 4.1. Because the nearer target does not meet a 3‑to‑1 ratio, the overall math only satisfies the 3‑to‑1 criterion thanks to the distant low.
What would change the picture
A weekly close above $25.65 would alter the narrative, as that level is defined as the point where the weekly trend would end. Any significant earnings surprise—either a material beat or miss on the upcoming earnings release scheduled for November 11—could also shift the balance of evidence.
What to watch
- November 11 earnings: the earnings per share figure and guidance will be the key number.
- Sector catalysts: any FDA approvals or biotech M&A activity that moves XLV could spill over to CAPR.
- Valuation: the consensus mean target of $27.25 remains 65% above the current price, highlighting a large valuation gap that could tighten if the stock moves toward the $10 resistance.